NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · Real-Time Price · USD
0.570
+0.122 (27.12%)
At close: Feb 21, 2025, 4:00 PM
0.500
-0.070 (-12.20%)
After-hours: Feb 21, 2025, 7:59 PM EST
NKGen Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
63
Market Cap
25.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 77.00K | -349.00K | -81.92% |
Dec 31, 2021 | 426.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNKGN News
- 1 day ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
- 3 days ago - NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site - GlobeNewsWire
- 9 days ago - NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 10 days ago - NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease - GlobeNewsWire
- 2 months ago - NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewsWire
- 3 months ago - NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - GlobeNewsWire
- 4 months ago - NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 4 months ago - NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - GlobeNewsWire